SITAGLIPTIN - Generic Drug Details

What are the generic drug sources for sitagliptin and what is the scope of patent protection?

Sitagliptin is the generic ingredient in four branded drugs marketed by Zydus Lifesciences, Azurity, Merck Sharp Dohme, Apotex, Sandoz, and Watson Labs Inc, and is included in six NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sitagliptin has four patent family members in four countries.

There are thirty-five drug master file entries for sitagliptin. Two suppliers are listed for this compound. There are twenty-five tentative approvals for this compound.

Summary for SITAGLIPTIN

International Patents:	4
US Patents:	4
Tradenames:	4
Applicants:	6
NDAs:	6
Drug Master File Entries:	35
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	103
Clinical Trials:	468
Patent Applications:	6,759
Drug Prices:	Drug price trends for SITAGLIPTIN
What excipients (inactive ingredients) are in SITAGLIPTIN?	SITAGLIPTIN excipients list
DailyMed Link:	SITAGLIPTIN at DailyMed

See drug prices for SITAGLIPTIN

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SITAGLIPTIN

Constraining patent/regulatory exclusivity:

10,925,871

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SITAGLIPTIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chong Kun Dang Pharmaceutical	PHASE4
Second Affiliated Hospital, School of Medicine, Zhejiang University	PHASE1
Case Comprehensive Cancer Center	PHASE2

See all SITAGLIPTIN clinical trials

Generic filers with tentative approvals for SITAGLIPTIN

Applicant	Application No.	Strength	Dosage Form
		50MG;1000MG	TABLET;ORAL
		50MG;500MG	TABLET;ORAL
		100MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for SITAGLIPTIN

Drug Class	Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for SITAGLIPTIN

A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

US Patents and Regulatory Information for SITAGLIPTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202425-003	Jan 20, 2026	AB	RX	No	No
Zydus Lifesciences	ZITUVIO	sitagliptin	TABLET;ORAL	211566-003	Oct 18, 2023		RX	Yes	Yes	10,925,871		Y
Zydus Lifesciences	ZITUVIO	sitagliptin	TABLET;ORAL	211566-001	Oct 18, 2023		RX	Yes	No	10,925,871		Y
Apotex	SITAGLIPTIN PHOSPHATE	sitagliptin phosphate	TABLET;ORAL	202425-002	Jan 20, 2026	AB	RX	No	No

EU/EMA Drug Approvals for SITAGLIPTIN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Xelevia	sitagliptin	EMEA/H/C/000762For adult patients with type-2 diabetes mellitus, Xelevia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Xelevia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2007-03-21
Merck Sharp & Dohme B.V.	Tesavel	sitagliptin	EMEA/H/C/000910For patients with type-2 diabetes mellitus, Tesavel is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination witha sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control;a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.Tesavel is also indicated as add on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2008-01-10
Merck Sharp and Dohme B.V	Januvia	sitagliptin	EMEA/H/C/000722For adult patients with type-2 diabetes mellitus, Januvia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Januvia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2007-03-20
Merck Sharp & Dohme B.V.	Ristaben	sitagliptin	EMEA/H/C/001234For adult patients with type-2 diabetes mellitus, Ristaben is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated-receptor-gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Ristaben is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Authorised	no	no	no	2010-03-15

International Patents for SITAGLIPTIN

Country	Patent Number	Title	Estimated Expiration
India	651MU2014
Philippines	12016501686	PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN
World Intellectual Property Organization (WIPO)	2015128877
South Africa	201606075	PHARMACEUTICAL COMPOSITIONS OF SITAGLIPTIN

Supplementary Protection Certificates for SITAGLIPTIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1084705	SPC/GB14/082	United Kingdom		PRODUCT NAME: SITAGLIPTIN; REGISTERED: UK EU/1/07/383/001-018 20070323; UK EU/1/07/382/001-018 20070323
1412357	122008000046	Germany		PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE SITAGLIPTINPHOSPHAT- MONOHYDRAT, IN KOMBINATION MIT METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 FIRST REGISTRATION: CH/LI 58450 01 58450 02 58450 03 20080408
1412357	42/2007	Austria		PRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE: EU/1/07/383/001-018 (MITTEILUNG) 20070323
1412357	106 4-2007	Slovakia		PRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE: EU/1/07/383/001 - EU/1/07/383/018 20070321

Sitagliptin market dynamics and financial trajectory (2010-2025): revenue exposure, competitive pressure, and exclusivity-driven risk

Last updated: June 20, 2026

Sitagliptin, a DPP-4 inhibitor marketed by multiple companies under brand names including Januvia and Janumet (with metformin), has shifted from patent-led growth to a multi-generic, low-margin market with ongoing formulary share capture by authorized generics and newer combinations. Financial trajectory is now dominated by (1) loss of US and major-country brand exclusivity for sitagliptin monotherapy and fixed-dose combinations, (2) price compression from generic entry, and (3) mix effects from combination products, payer steering, and manufacturer portfolio rationalization.

---

How big is the sitagliptin market and how has revenue trended since generic entry?

Short answer: Sitagliptin’s peak brand revenues have flattened and then declined after generic penetration in core markets. Current revenue is primarily sustained by (a) combination brands (notably sitagliptin/metformin), (b) brand survival strategies in selected geographies with slower adoption, and (c) authorized generic supply chains.

US revenue and brand trajectory: Januvia and Janumet

• Januvia (sitagliptin 25/50/100 mg): Brand sales peaked pre-generic entry and declined after generic launches. Post-loss period is characterized by continued but reduced volume and shrinking net price.
• Janumet (sitagliptin/metformin immediate and XR): Combination dynamics typically slow erosion versus monotherapy, but fixed-dose combo net price still compresses after generic penetration.

What drives the slope:

• Payer formularies shifted toward lowest net-cost generics and preferred DPP-4 or alternative classes.
• Claims substitution increased as generic sitagliptin and combination products gained coverage breadth.
• Competition from GLP-1 RAs and SGLT2 inhibitors reduced addressable patient growth at the margin, even in DPP-4-heavy portfolios.

Ex-US dynamics

• Europe: Uptake of generic sitagliptin has progressed unevenly by country, producing delayed but eventually steep price compression.
• Emerging markets: Delayed generic availability in some regions historically supported longer brand monetization, but volume benefits have narrowed as local and international generics scaled.

---

When does sitagliptin lose exclusivity in the US, EU, and key markets?

Short answer: US and major markets have moved through primary exclusivity windows for sitagliptin and key combinations. The current market is in the post-brand phase where competitive entry is governed by patent-specific tails (formulations, methods, combination patents) and regulatory exclusivity periods rather than core composition IP.

What exclusivity mattered commercially

For sitagliptin, exclusivity and patent life determined:

• earliest generic entry dates for monotherapy,
• combination product durability (Janumet),
• ability of brand to block certain dosage forms or specific formulation approaches.

Timeline framework (how to map revenue risk

• Pre-generic: brand can price with limited substitution risk.
• At first generic entry: volume decline accelerates and net price resets.
• After multiple entrants: price bottoms and margins compress across the supply chain.
• Post-tail patents: occasional niche durability occurs if specific formulation or method claims hold. In practice, sitagliptin has increasingly behaved like a fully genericized product in many geographies.

---

What patents protect sitagliptin and sitagliptin/metformin combinations, and how does that affect market access?

Short answer: The sitagliptin estate has historically included composition, formulation, combination, and method-of-use claims, but current market access is largely controlled by whether specific Orange Book-listed patents still block or delay ANDA and 505(b)(2) approvals in given dosage forms.

Orange Book status: what matters for market timing

When evaluating generic entry risk, the key inputs are:

• Orange Book listing for each product/dosage form,
• patent expiration dates,
• whether challenges were filed as Paragraph IV,
• whether litigation produced settlements (often license or “carve-out” launch dates).

Formulation and fixed-dose combo durability

Combination products like Janumet and XR variants often have distinct patent sets than monotherapy. That structure can delay erosion in certain dosage strengths while monotherapy becomes fully commoditized.

---

How many generics compete in sitagliptin now, and what does that do to price and margins?

Short answer: Sitagliptin has moved into a high-competition state in the US and major markets with multiple generic suppliers. That environment is associated with:

• rapid net price decline after initial entry,
• churn driven by lowest-cost contracting and wholesale channel incentives,
• margin pressure for both generics and any authorized brand channel participants.

Competition mechanics

• Wholesale channel dynamics: PBM and wholesaler contracting tends to drive sitagliptin pricing downward quickly once a second and third supplier enters.
• Authorized generics (AGs): When present, AG supply can accelerate substitution while reducing branded leverage.
• Multiple strengths and dosing schedules: Fixed-dose combinations multiply the SKU count, increasing the rate at which at least some SKUs gain broad coverage through generic substitution.

Resulting margin profile

• Brand margins compress after generic entry.
• Generic margins also compress as manufacturing capacity scales and pricing approaches competitive parity.

---

What Paragraph IV challenges were filed for sitagliptin, and how did litigation affect generic launch timing?

Short answer: Generic entry into sitagliptin has been shaped by Paragraph IV ANDA challenges and settlement outcomes. These processes determine when the first and subsequent generic products can launch for each listed Orange Book patent.

Where litigation timing shows up in financials

• Brand revenue step-down: usually occurs around the first meaningful generic launch.
• Stabilization after step-down: can occur once the market’s price settles and volume is maintained by existing prescriptions and switching inertia.
• Second wave effects: occur when additional patents fall away for dosage forms or combination products, prompting further erosion.

(For a transaction-grade view, the litigation data has to be mapped patent-by-patent to launch dates and settlements. Without a complete patent-by-patent record in the input, a definitive list of specific case numbers, settlements, and launch triggers cannot be produced here.)

---

How does sitagliptin compare with competing diabetes classes for market share and revenue outlook?

Short answer: In the broader diabetes market, DPP-4 inhibitors have faced share headwinds from GLP-1 RAs and SGLT2 inhibitors, particularly in patients where outcomes data and payer incentives favor newer agents. Sitagliptin’s role is increasingly maintenance therapy or step-in after earlier lines, which limits growth even before generic pricing is considered.

Key competitor clusters

• GLP-1 receptor agonists: higher uptake for weight and CV risk profiles; stronger payer support in many formularies.
• SGLT2 inhibitors: increasing first-line and comorbidity-driven prescribing; can reduce DPP-4 utilization.
• Other DPP-4 inhibitors: class competition intensifies as most members become generic.

Net effect on sitagliptin economics

• Volume growth slows as prescribers move to newer agents.
• Price compression increases due to generic competition.
• Combined effect yields more defensive revenue rather than growth.

---

What is the biosimilar risk profile for sitagliptin (and why is it effectively not relevant)?

Short answer: Sitagliptin is a small-molecule drug, so biosimilar frameworks do not apply. The relevant market-access risk is generic competition under ANDA and patent exclusivity tails, not biologic follow-on entry.

---

What formulations and product lifecycle segments drive sitagliptin revenue today?

Short answer: Revenue exposure is concentrated in fixed-dose combinations and specific tablet strengths and XR/IR formats where formulary coverage persists after generic erosion.

Monotherapy vs combination: typical mix logic

• Monotherapy: most fully commoditized; largest price compression.
• Fixed-dose combos: mix durability can persist longer because prescribers and payers manage combo dosing and switching behavior.

XR vs IR

XR versions can retain higher coverage or better patient adherence in certain segments, but generic XR competition typically accelerates once formulation-specific barriers fall.

---

What commercial and payer dynamics most affect sitagliptin net sales?

Short answer: Net sales are driven less by science-led differentiation and more by purchasing economics, formulary status, and pharmacy benefit design.

Payer steering variables

• Formulary tiering: DPP-4 inhibitor tiers compress as generics proliferate.
• Copay structures: lower-cost generics reduce brand script conversion resistance.
• Step edits and prior authorization: often applied to higher-cost alternatives rather than to sitagliptin after generic entry.

Manufacturer portfolio rationalization

Post-peak periods frequently show:

• divestitures,
• license re-negotiations,
• supply agreements optimizing channel volume.

These moves can stabilize volume but do not halt price compression.

---

Which companies currently compete most aggressively for sitagliptin share?

Short answer: Generic manufacturers and authorized generic participants are the primary competitive force. Brand-holder economics depend on remaining branded share where payer coverage is conservative and on combination products where generic substitution takes time.

A complete company-by-company competitive map requires Orange Book and ANDA market status data by dosage form, which is not included in the provided input set. Without it, naming specific generic suppliers and their entry timing would be incomplete.

---

Revenue exposure: how dependent are business lines on sitagliptin and related combinations?

Short answer: Sitagliptin’s revenue exposure has generally shifted from “category growth” to “portfolio defense,” with the economic sensitivity now tied to:

• how quickly branded units convert to generics in each market,
• how resilient combination product mix remains,
• how aggressively payers switch to lowest net-cost SKUs.

For brand holders or license partners, sitagliptin becomes one driver among many, and its incremental contribution often declines after generic entry.

---

Key timelines for decision-making: exclusivity tail, generic waves, and switching windows

Short answer: Decision timing in sitagliptin’s life cycle is governed by remaining patent tails for specific SKUs and by formulary switching cadence after generic launches.

How to use timelines operationally

• Pre-launch planning: map each dosage form’s listed patents and known launch history.
• Market entry risk gates: treat each SKU and strength as a separate risk line item.
• Litigation settlement events: convert to expected launch dates and volume substitution assumptions.

---

Key Takeaways

• Sitagliptin’s financial trajectory is dominated by generic penetration and class-level share headwinds from GLP-1 RAs and SGLT2 inhibitors.
• Combination products (sitagliptin/metformin, including XR/IR formats) have shown greater durability than monotherapy, but they still face sustained price compression as generic options expand.
• Current market dynamics are governed by payer formulary design, net-cost contracting, and SKU-level patent tails rather than by clinical differentiation.
• Biosimilar risk is not applicable for sitagliptin; the main market-access threat is ANDA-based generic entry and patent-expiration timing.

---

FAQs

1) What is the main driver of sitagliptin price erosion after generic entry?
Net-price compression driven by multi-source generic competition, PBM/wholesaler contracting, and formulary tier changes.

2) Does sitagliptin/metformin (Janumet) lose market share more slowly than Januvia?
Typically yes, because fixed-dose combination mix and dosing inertia can slow substitution, but erosion still accelerates as generics cover the main SKUs.

3) Are there delivery-form or strength-specific risks that change generic entry timing for sitagliptin?
Yes. Different tablet strengths and XR versus IR formulations can have separate patent and Orange Book listing profiles.

4) What competitive class is most likely to reduce new sitagliptin starts?
GLP-1 receptor agonists and SGLT2 inhibitors, where payer incentives and patient comorbidity profiles favor outcomes-based prescribing.

5) Is biosimilar entry a threat to sitagliptin’s sales?
No. Sitagliptin is a small molecule; follow-on competition occurs through generic pathways, not biosimilars.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. U.S. Food and Drug Administration. Drug Approval Reports / NDA and ANDA databases (Sitagliptin and sitagliptin/metformin products). FDA.
3. FDA. Orange Book patent and exclusivity guidance materials. FDA.
4. Bloomberg Intelligence. Pharmaceuticals datasets and pipeline/market-access analytics (industry standard sources).